Abstracts tagged "cancer and scleroderma"

Abstract Number: 1902 • 2015 ACR/ARHP Annual Meeting
Systemic Sclerosis and Lung Cancer Risk: Data from the Canadian Scleroderma Research Group
Lama Sakr¹, Elie Younanian², Marie Hudson³, Mianbo Wang⁴, Murray Baron⁵ and Sasha Bernatsky⁶, ¹Division of Pulmonary Diseases, Jewish General Hospital, Montreal, QC, Canada, ²Division of Pulmonary Diseases, McGill University, Montreal, QC, Canada, ³McGill University, Jewish General Hospital, Montreal, QC, Canada, ⁴Lady Davis Institute for Medical Research, Montreal, QC, Canada, ⁵Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, QC, Canada, ⁶Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: The literature supports an increased incidence of certain malignancies in patients with systemic sclerosis (SSc), including lung cancers. Predictors of lung cancer in SSc…
Abstract Number: 1703 • 2014 ACR/ARHP Annual Meeting
An Association of Anti-PM/Scl Antibody Reactivity with Risk of Malignancy in Scleroderma
Cosimo Bruni¹, Ana Lages², Hitesh Patel³, Jennifer Harvey³, Voon H. Ong⁴, Marco Matucci-Cerinic¹, Emma C. Derrett-Smith⁵ and Christopher P Denton⁶, ¹Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ²Affiliation servicio de Medicina Interna, Hospital De Braga, Braga, Portugal, ³Department of Clinical Immunology, Royal Free Hospital, London, United Kingdom, ⁴Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School Royal Free Campus, London, United Kingdom, ⁵Centre for Rheumatology and Connective Tissue Diseases,, UCL Medical School Royal Free Campus, London, United Kingdom, ⁶Centre for Rheumatology and Connective Tissue Disease, UCL Medical School Royal Free Campus, London, United Kingdom
Association of anti-PM/Scl antibody with risk of malignancy in scleroderma. C. Bruni¹, A. Lages², H. Patel3, J. Harvey3, V. Ong4, M. Matucci-Cerinic¹, E. Derrett-Smith4, C.P.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].